By Attending this Complimentary CME Event

“Advances in the Treatment of Chronic Liver Disease and Thrombocytopenia”

Fresno, CA
Wednesday, August 28
12:30 – 1:30pm
Shehadey Pavilion at
Saint Agnes Medical Center
1303 E Herndon Avenue

The number of patients with End-State Liver Disease in the United States is expected to continue to grow dramatically in the next ten years. This is largely due to the burden of chronic viral hepatitis which already exists in our population. As these patients age, a larger number will develop decompensation events such as variceal bleeding, hepatic encephalopathy, hepatocellular carcinoma, hyponatremia and renal failure.

Thrombocytopenia (platelet count <150,000/μL) is a common complication in patients with chronic liver disease and has been observed in up to 76% of patients. Thrombocytopenia can impact routine care of patients with CLD, potentially postponing or interfering with diagnostic and therapeutic procedures including liver biopsy, antiviral therapy, and medically indicated or elective surgery.

Currently, many patients undergo platelet transfusions prior to treatment procedure. This adds time, cost and patient discomfort. New therapeutic options to safely and effectively raise platelet levels and the most promising can stimulate Thrombopoietin (TPO) production. This significantly reduces the need for platelet transfusions and facilitates the use of antiviral therapy and other medically indicated treatments in patients with liver disease.

This seminar will address:
- The causes and complications of chronic liver disease
- Cirrhosis, Gastroesophageal bleeding and the Liver transplant process
- Promising treatments for Thrombocytopenia in liver disease patients

Those who complete this activity will better understand how to screen, diagnose and effectively treat their patients and be more confident of when and how to refer to a Hepatologist for more advanced care.

There is no charge for this event, but space is limited and pre-registration is required.

For More Information and to Register:

Your Course Faculty
Robert G. Gish, MD
Asst. Professor of Medicine
Stanford University

Joint Provider Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Louisville School of Medicine and SC Liver Research Consortium. The University of Louisville School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statements
Physicians - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for 1.5 continuing education credits through University of Louisville Hospital, provider number 4-0068-7-18-1063. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

Nurse Practitioners and Physician Assistants - AANP and AAPA accept Category 1 credit from AMA PRA Category 1 Credit(s)™ organizations accredited by ACCME.

This course is supported, in part, by educational grants from industry, in accordance with ACCME accreditation Standards for Commercial Support. At the time this brochure was developed, a complete listing of commercial supporters is not available. Appropriate acknowledgement will be given to all supporters at the time of the educational activity.